Stocks TelegraphStocks Telegraph
Stock Ideas

YMAB Stock Performance and Key Statistics

NASDAQ : YMAB

Y-mAbs Therapeutics

$8.61
0.02+0.23%
At Close 4:00 PM
Not Actively Trading
58.26
BESG ScoreESG Rating

stock performance chart

YMAB Fundamental Analysis

Based on recent data, Y-mAbs Therapeutics, Inc. (YMAB) shows an Average True Range (ATR) of 0.09 and an Enterprise Value of 592.13M. Its average trading volume over the past 3 months is N/A, indicating liquidity. These fundamental metrics provide insight into YMAB's underlying financial health and market activity.

ATR0.09
Enterprise Value592.13M
Avg Vol (3 Months)-
Avg Vol (10 Days)-

YMAB Technical Analysis Indicators

Y-mAbs Therapeutics, Inc. (YMAB) technical indicators as of February 20, 2026: the SMA 20 is 0.61%, SMA 50 at 25.84%, and SMA 200 at 40.75%. The RSI 14 value is 81.2, suggesting its current momentum. These technical analysis signals help assess YMAB's price trends and potential future movements.

SMA 200.61%
SMA 5025.84%
SMA 20040.75%
RSI 1481.2

YMAB Stock Performance Overview

Y-mAbs Therapeutics, Inc. (YMAB) stock performance overview as of February 20, 2026: The 52-week high is $8.61 (currently -46.55% below), and the 52-week low is $3.55 (currently 142.54% above). Over the past year, YMAB's performance is N/A, compared to the S&P 500's 7.5% change.

52-Week High8.61
52-Week High Chg-46.55%
52-Week Low3.55
52-Week Low Chg+142.54%
S&P 500 52-Week Chg7.5%

Y-mAbs Therapeutics, Inc. (YMAB) Historical Stock Performance

According to market data, Y-mAbs Therapeutics, Inc. (YMAB) stock's recent performance metrics show that over the last month, YMAB is 1.18%, with a Year-to-Date (YTD) performance of 9.96%. Over the past year, the stock has seen a N/A change. These figures summarize YMAB's price movements across various periods, reflecting its historical returns.

Period1 Week1 MonthQuarterHalf Year1 YearYTD
High8.618.618.618.618.61N/A
Low8.578.513.93.553.55N/A
Performance+0.23%+1.18%+82.80%+82.03%-+9.96%

Industry Analysis and Valuation

According to current financial data, YMAB stock's P/E (TTM) ratio is -17.56, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.23. Key valuation ratios for YMAB, including P/S (4.58), P/B (4.46), and P/FCF (-21.83), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.

ValuationYMABSector MedianIndustry AvgS&P 500
P/E (TTM)-17.56-1.23-5.1632.59
P/S (TTM)4.583.71464.925.98
P/B (TTM)4.46175.399.285.23
P/FCF (TTM)-21.83-8.06-216.6830.63

Frequently Asked Questions

How is YMAB price-to-earnings ratio currently?
YMAB has a current P/E ratio of -17.56
How are YMAB's price-to-sale and price-to-book ratios?
The YMAB stock has a trailing twelve month price-to sales (P/S) ratio of 4.58 while its price-to-book (P/B) value is 4.46.
Is Y-mAbs Therapeutics, Inc.'s price-to-cashflow ratio high or low?
YMAB's price-to-free-cashflow (P/FCF) ratio is -21.83, an indicator that is currently being trending upward.
What's current simple moving average (SMA) for YMAB?
Based on YMAB's recent bid, its distance from 20 days simple moving average is 0.61%. It is 25.84% apart from 50 days simple moving average, and it is 40.75% apart from 200 days simple moving average.
What is the 52-week price range for YMAB?
The 52-week high for YMAB is $16.11 which is -46.55% away from the current price level whereas the distance of that from the 52-week low of $3.55 stands at 142.54%.
An overview of YMAB's stock performance: how did it fare?
The performance of YMAB stock was not encouraging with most of its significant price indicators in green. Y-mAbs Therapeutics, Inc.(NASDAQ: YMAB) shares have moved upward +0.23% or $0.02 in the latest trading session and have gained 9.96% year-to-date (YTD). The stock has lost nearly N/A over the past year. After moving 82.8% over the trailing 3-month period, the stock is 82.03% higher in the 6-month period. Looking at its performance over the shorter term, it'sgained 0.23% a week and 1.18% a month.
What is YMAB's 14-day relative strength index (RSI)?
The current 14-day RSI for YMAB stock is 81.2. Investors and traders alike rely on the relative strength index, or RSI, as an oscillating indicator. In terms of values, the RSI operates within a range ranging from 0 to 100. A rising RSI line indicates strength in the shares. As the RSI line falls, the opposite occurs. It is possible to examine different time periods when using the RSI indicator. Shorter time frames can cause the RSI to be more volatile. Most traders pay close attention to the marks between 30 and 70 on the RSI scale. When the stock price moves over 70, it is often considered to be an indicator of overbought conditions. Dropping below 30 indicates oversold territory. These levels are often used by traders to forecast stock price reversals.
For YMAB, what is the average true range (ATR) for the past two weeks?
ATR stands for Average True Range, which may be useful when traders or investors are assessing technical inventory. Currently, Y-mAbs Therapeutics, Inc. (YMAB) has a 14-day ATR of 0.09.
What is YMAB's current enterprise value?
After closing at $8.59 with 45.44M of its shares outstanding, the current enterprise value of YMAB is roughly 592.13M.
Over the past year, how has the stock price of YMAB changed?
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) is down N/A when it comes to the percentage price change over the past 52-weeks. The percentage price change came less than that of broader S&P 500 index that came at a fall of 7.5%. YMAB stock price is also up 9.96% on its value in year-to-date trading.
What is the average trading volume for YMAB shares?
The number outstanding shares of YMAB is 45.44M, and of these 75.9% shares are freely available for trading. On average, YMAB stock has traded - shares per day for the past 10 days. A total of 760.68K shares changed hands during the last trading session with the average session volume of 905.07K shares.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph